This database contains 429 studies, archived under the term: "USA"
Click here to filter this large number of results.
Exploring the effectiveness of an internet-based program for reducing caregiver distress using the iCare Stress Management e-Training Program
Kajiyama, Bruno,
Thompson, Larry W.,
Eto-Iwase, Tamiko,
Yamashita, Mio,
Di Mario, John,
Marian Tzuang, Yuan,
Gallagher-Thompson, Dolores
Objective: Determine if the online iCare Stress Management e-Training Program reduces stress, bother, depression, and poor life quality for dementia family caregivers (CGs).; Method: CGs (N = 150) were randomly assigned to the iCare Condition (ICC) or to the Education/Information-Only Condition (EOC) for a 3-month period. Change in self-report measures of stress (PSS) (primary outcome), […]
Treatment outcomes of a crisis intervention program for dementia with severe psychiatric complications: the Kansas bridge project
Johnson, D. K.,
Niedens, M.,
Wilson, J. R.,
Swartzendruber, L.,
Yeager, A.,
Jones, K.
Purpose: Although declines in memory and attention are hallmark symptoms of Alzheimer’s disease (AD), noncognitive symptoms are prevalent. Over 80% of individuals will experience neuropsychiatric symptoms, which complicates symptom profiles. Research indicates a community-integrated response to dementia crisis can reduce negative consequences attributed to crisis including increased caregiver burden, increased health care costs, and premature […]
Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use
Jacobs, Emily G.,
Kroenke, Candyce,
Lin, Jue,
Epel, Elissa S.,
Kenna, Heather A.,
Blackburn, Elizabeth H.,
Rasgon, Natalie L.
Apolipoprotein-ε4 (APOE-ε4) is a major genetic risk factor for cognitive decline, Alzheimer’s disease (AD) and early mortality. An accelerated rate of biological aging could contribute to this increased risk. Here, we determined whether APOE-ε4 status impacts leukocyte telomere length (TL) and the rate of cellular senescence in healthy mid-life women and, further, whether hormone replacement […]
Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study
Jackson, Graham S.,
Burk-Rafel, Jesse,
Edgeworth, Julie Ann,
Sicilia, Anita,
Abdilahi, Sabah,
Korteweg, Justine,
Mackey, Jonathan,
Thomas, Claire,
Wang, Guosu,
Schott, Jonathan M.,
Mummery, Catherine,
Chinnery, Patrick F.,
Mead, Simon,
Collinge, John
Importance: Our study indicates a prototype blood-based variant Creutzfeldt-Jakob disease (vCJD) assay has sufficient sensitivity and specificity to justify a large study comparing vCJD prevalence in the United Kingdom with a bovine spongiform encephalopathy-unexposed population. In a clinical diagnostic capacity, the assay’s likelihood ratios dramatically change an individual’s pretest disease odds to posttest probabilities and […]
Nursing homes and end-of-life care in Japan
Objectives: To describe end-of-life care in Japanese nursing homes by comparing facility and characteristics of residents dying in nursing homes with those who had been transferred and had died in hospitals, and by comparing the quality of end-of-life care with hospitals and with their respective counterparts in the United States.; Setting: National sample of 653 […]
Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: A phase 2, randomised, double-blind, placebo-controlled trial
Background: PBT2 is a metal protein-attenuating compound that might reduce metal-induced aggregation of mutant huntingtin and has prolonged survival in a mouse model of Huntington’s disease. We aimed to assess the safety, tolerability, and efficacy of PBT2 in patients with Huntington’s disease. Methods: In this 26-week, randomised, double-blind, placebo-controlled trial, adults (≥ 25 years old) […]